We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,143

Consumer Protection in Retail: Weekly Roundup
  • Hunton & Williams LLP
  • USA
  • March 27 2018

Nectar Brand LLC has agreed to stop making unqualified claims that its mattresses were made in the United States. According to the FTC's complaint

FDA Draft Guidance Proposes Risk-Based Regulatory Scheme for Drug Products Labeled as Homeopathic
  • Haynes and Boone LLP
  • USA
  • March 12 2018

More than two and a half years after the U.S. Food and Drug Administration (FDA) announced that it was re-evaluating its regulatory framework for

Checking in with the FTC’s Bureau of consumer protection - trends, highlights, new developments and what lies ahead
  • Hogan Lovells
  • USA
  • February 28 2018

The Federal Trade Commission (FTC) Bureau of Consumer Protection is where the action is when it comes to identifying current and future trends related

Top 7 Legal Challenges Facing Physicians and Hospitals
  • Jackson Lewis PC
  • USA
  • February 21 2018

The American Health Lawyers Association’s 2018 Physicians and Hospitals Law Institute in New Orleans focused on the legal challenges faced by

FDA, FTC Try to Stop Opioid Cessation Products
  • Manatt Phelps & Phillips LLP
  • USA
  • February 8 2018

Marketers of opioid cessation products received warning letters from the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC

FDA & FTC Issue Joint Warning Letters to Companies Marketing Products to Overcome Opioid Addiction and Withdrawal
  • Kelley Drye & Warren LLP
  • USA
  • January 24 2018

The FDA & FTC today posted warning letters to 11 marketers and distributors of opioid cessation products, alleging that such products were unapproved

NDAANDA Holders Must Affirmatively Submit Data to FDA or Risk Losing Products’ Active Listing in The Orange Book
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 18 2018

Pharmaceutical industry stakeholders know that drug prices, market competition, supply chain challenges, and shortages of critical drug products have

Life Sciences & Antitrust: Cases to Watch in 2018
  • Paul Hastings LLP
  • USA
  • January 17 2018

The intersection of complex drug competition frameworks and the antitrust laws continues to grow. With increased collaboration between the Food and

FDA Resets Enforcement Priorities for OTC Homeopathic Drugs
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • January 2 2018

Happy New Year! And now on to your regular Consumer Product Matters programming Another Federal agency with a consumer-protection mandate has taken a

Regulatory Roundup - December 2017
  • Crowell & Moring LLP
  • USA
  • December 20 2017

On October 26, 2017, CPSC issued a Final Decision and Order holding that Zen Magnets and Neoballs rare-earth magnet sets (Zen Magnets) are a